The piperidinone-based molecular compound AMG232, able to selectively inhibit MDM2-p53 interaction, has shown a significative anti-tumor efficacy in a large panel of tumor cell lines as well as in mouse models [102]. This evidence concerns the gene TP53 and neoplasm.